Pharmakokinetik von Imatinib (STI571) und seinem Hauptmetaboliten N-Desmethyl-Imatinib

Schlüsselwörter

GIST - Imatinib - STI 571 - N-Desmethyl-Imatinib - Pharmakokinetik

Literatur

• 1 Druker B J, Talpaz M, Resta D J. et al . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.  N Engl J Med. 2001;  344 1031-1037
• 2 Kantarjian H M, O’Brien S, Cortes J E. et al . Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.  Clinical Cancer Research. 2002;  8 2167-2176
• 3 Sawyers C L, Hochhaus A, Feldman E. et al . A phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia positive chronic myeloid leukemia in myeloid blast crisis.  Blood. 2000;  96 503 a
• 4 Hochhaus A, Kantarijan H M, Sawyers C L. et al . Glivec® (Imatinib Mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloic leukemia in late chronic phase: results of a phase II study.  Hematol. 2001;  J 1 (Suppl) 199
• 5 Druker B J, Sawyers C L, Kantarjian H. et al . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.  N Engl J Med. 2001;  344 (14) 1038-1042
• 6 Ottmann O G, Sawyers C L, Druker B. et al . Phase II study of STI571 in adult patients with Philadelphia chromosome (Ph) positive acute leukemias.  Hematol. 2001;  J 1 (Suppl) 93
• 7 le C outre P, Tassi E, Varella-Garcia M. et al . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.  Blood. 2000;  95 1758-1766
• 8 Bakhtiar R, Lohne J, Ramos L. et al . High-throughput quantification of the anti-leukemia drug STI571 (GleevecE) and its main metabolite (CGP 74 588) in human plasma using liquid chromatography-tandem mass spectrometry.  Journal of Chromatography B. 2002;  768 325-340
• 9 Heinzel G, Hammer R, Wolf M. et al . Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models.  Arzneimittelforschung. 1977;  27 904
• 10 Peng B, Dutreix C, Mehring G. et al . Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.  J Clin Pharmacol. 2004;  44 158